Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) — The “Ovarian Cancer Drugs Market Size, Share & Trends Analysis, 2023-2030” report has been added to ResearchAndMarkets.com’s offering.
The global ovarian cancer drugs market is poised for significant growth with a projected market size of USD 5.65 billion by 2030, expanding at a compound annual growth rate (CAGR) of 6.6% from 2023 to 2030. This growth trajectory is influenced by factors such as the introduction of novel therapeutic agents, strong drug development pipelines, and a rising incidence of ovarian cancer attributed to demographic changes and lifestyle factors.
In the realm of treatment developments, the shift towards non-platinum based Poly ADP-Ribose Polymerase (PARP) inhibitors and Vascular Endothelial Growth Factor (VEGF) inhibitors for second and third-line ovarian cancer therapies has revolutionized standard treatment protocols. Furthermore, the market is witnessing an expansion due to the emergence of promising new therapies, including angiogenesis inhibitors and antibody drug conjugates (ADCs).
Key Market Insights
- Hospital pharmacies commanded the largest revenue share in 2022, recognizing the significance of access to innovative ovarian cancer treatments in hospital settings backed by government initiatives and funding for cancer research.
- The commercial segment leads the market, with patent expiries of branded drugs paving the way for generics and increased chronic disease prevalence fueling this growth.
- With a notable CAGR, the online pharmacy segment is emerging as a growth leader in the ovarian cancer drugs market, offering accessibility and convenience to patients seeking treatment.
- North America retains its dominance of the global market share due to factors such as high ovarian cancer incidence, driving the demand for effective treatments, and fostering pharmaceutical research.
- The Asia Pacific region is projected to experience the fastest growth, attributed to increased clinical trial activity, which is vital in introducing innovative treatments to the market and driving drug development.
Regional Highlights and Trends:
Through detailed analysis, the report highlights the significant impact of regional dynamics and epidemiological trends on market development:
- In North America, the ovarian cancer drugs market stands bolstered by a sustained demand from a significant patient population facing high incidence rates. The American Cancer Society’s 2023 estimates underscore the urgency for advanced therapeutic interventions.
- The Asia Pacific market is set to outpace others, with a remarkable surge in clinical trial activity enhancing patient access to novel treatments and attracting global pharmaceutical innovation to the region.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 94 |
| Forecast Period | 2022-2030 |
| Estimated Market Value (USD) in 2022 | $3.37 Billion |
| Forecasted Market Value (USD) by 2030 | $5.65 Billion |
| Compound Annual Growth Rate | 6.6% |
| Regions Covered | Global |
Companies Mentioned
- AbbVie Inc.
- Pfizer, Inc.
- AstraZeneca
- F. Hoffmann-La Roche AG
- Johnson & Johnson Services, Inc.
- Boehringer Ingelheim International GmbH
- Clovis Oncology
- ImmunoGen, Inc.
- Vivesto AB
For more information about this report visit https://www.researchandmarkets.com/r/9g15vd
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Global Ovarian Cancer Drugs Market
